TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
MARKET SHARE 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Substitutes 20
Rivalry 21
LEADING COMPANIES 22
Eu Yan Sang International 22
Johnson & Johnson 26
Bayer AG 31
MARKET DISTRIBUTION 36
MARKET FORECASTS 37
Market value forecast 37
MACROECONOMIC INDICATORS 38
APPENDIX 40
Methodology 40
Industry associations 41
Related Datamonitor research 41
Disclaimer 43
ABOUT DATAMONITOR 44
Premium Reports 44
Summary Reports 44
Datamonitor consulting 44
LIST OF TABLES
Table 1: Singapore OTC pharmaceuticals market value: $ million, 2005–09 10
Table 2: Singapore OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Table 3: Singapore OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Table 4: Singapore OTC pharmaceuticals market share: % share, by value, 2009 13
Table 5: Eu Yan Sang International: key facts 22
Table 6: Eu Yan Sang International: key financials ($) 24
Table 7: Eu Yan Sang International: key financials (Si$) 24
Table 8: Eu Yan Sang International: key financial ratios 24
Table 9: Johnson & Johnson: key facts 26
Table 10: Johnson & Johnson: key financials ($) 28
Table 11: Johnson & Johnson: key financial ratios 29
Table 12: Bayer AG: key facts 31
Table 13: Bayer AG: key financials ($) 34
Table 14: Bayer AG: key financials (€) 34
Table 15: Bayer AG: key financial ratios 34
Table 16: Singapore OTC pharmaceuticals market distribution: % share, by value, 2009 36
Table 17: Singapore OTC pharmaceuticals market value forecast: $ million, 2009–14 37
Table 18: Singapore size of population (million), 2005–09 38
Table 19: Singapore gdp (constant 2000 prices, $ billion), 2005–09 38
Table 20: Singapore gdp (current prices, $ billion), 2005–09 38
Table 21: Singapore inflation, 2005–09 39
Table 22: Singapore consumer price index (absolute), 2005–09 39
Table 23: Singapore exchange rate, 2005–09 39
LIST OF FIGURES
Figure 1: Singapore OTC pharmaceuticals market value: $ million, 2005–09 10
Figure 2: Singapore OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Figure 3: Singapore OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Figure 4: Singapore OTC pharmaceuticals market share: % share, by value, 2009 13
Figure 5: Forces driving competition in the OTC pharmaceuticals market in Singapore, 2009 14
Figure 6: Drivers of buyer power in the OTC pharmaceuticals market in Singapore, 2009 16
Figure 7: Drivers of supplier power in the OTC pharmaceuticals market in Singapore, 2009 17
Figure 8: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Singapore, 2009 18
Figure 9: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Singapore, 2009 20
Figure 10: Drivers of degree of rivalry in the OTC pharmaceuticals market in Singapore, 2009 21
Figure 11: Eu Yan Sang International: revenues & profitability 25
Figure 12: Eu Yan Sang International: assets & liabilities 25
Figure 13: Johnson & Johnson: revenues & profitability 29
Figure 14: Johnson & Johnson: assets & liabilities 30
Figure 15: Bayer AG: revenues & profitability 35
Figure 16: Bayer AG: assets & liabilities 35
Figure 17: Singapore OTC pharmaceuticals market distribution: % share, by value, 2009 36
Figure 18: Singapore OTC pharmaceuticals market value forecast: $ million, 2009–14 37
[Inhaltsverzeichnis ausblenden]
